|Bid||17.00 x 800|
|Ask||40.00 x 1200|
|Day's Range||21.24 - 22.32|
|52 Week Range||6.99 - 28.36|
|Beta (5Y Monthly)||2.20|
|PE Ratio (TTM)||206.26|
|Earnings Date||Nov 30, 2021 - Dec 06, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.25|
Avid Bioservices (CDMO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
On today's call, we have Nick Green, President and CEO; and Dan Hart, Chief Financial Officer. Today, we'll be providing an overview of Avid Bioservices' contract development and manufacturing business, including updates on corporate activities and financial results for the quarter ended July 31, 2021.
-- Recorded First Quarter Revenue of $30.8 Million -- -- Achieved Fifth Consecutive Quarter of Operational Profitability -- -- Signed $23 Million in New Business Orders and Ended the Quarter with a Backlog of $110 Million -- -- Phase 1 and Phase 2 Expansion Efforts Advancing as Planned -- TUSTIN, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by prov